Literature DB >> 15668426

Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.

L L Chao1, N Schuff, J H Kramer, A T Du, A A Capizzano, J O'Neill, O M Wolkowitz, W J Jagust, H C Chui, B L Miller, K Yaffe, M W Weiner.   

Abstract

BACKGROUND: N-acetylaspartate (NAA) in the medial temporal lobe (MTL) and parietal lobe gray matter (GM) is diminished in Alzheimer disease (AD). Because NAA is considered a marker of neuronal integrity, reduced medial temporal and parietal lobe NAA could be an early indication of dementia-related pathology in elderly individuals.
OBJECTIVES: 1) To determine whether cognitively impaired but nondemented (CIND) elderly individuals exhibit a similar pattern of reduced medial temporal and parietal lobe NAA as AD patients. 2) To compare regional NAA patterns, hippocampal and neocortical gray matter (GM) volumes in CIND patients who remained cognitively stable and those who became demented over 3.6 years of follow-up. 3) To examine the relationship between memory performance, medial temporal lobe NAA, and hippocampal volume.
METHODS: Seventeen CIND, 24 AD, and 24 cognitively normal subjects were studied using MRSI and MRI.
RESULTS: Relative to controls, CIND patients had reduced MTL NAA (19 to 21%, p = 0.005), hippocampal (11 to 14%, p < or = 0.04), and neocortical GM (5%, p = 0.05) volumes. CIND patients who later became demented had less MTL NAA (26%, p = 0.01), hippocampal (17 to 23%, p < or = 0.05), and neocortical GM (13%, p = 0.02) volumes than controls, but there were no significant differences between stable CIND patients and controls. MTL NAA in combination with hippocampal volume improved discrimination of CIND and controls over hippocampal volume alone. In AD and CIND patients, decreased MTL NAA correlated significantly with impaired memory performance.
CONCLUSION: Reduced medial temporal lobe N-acetylaspartate, together with reduced hippocampal and neocortical gray matter volumes, may be early indications of dementia-related pathology in subjects at high risk for developing dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668426      PMCID: PMC1851679          DOI: 10.1212/01.WNL.0000149638.45635.FF

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Spatial localization in NMR spectroscopy in vivo.

Authors:  P A Bottomley
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

3.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

4.  Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.

Authors:  N Schuff; A A Capizzano; A T Du; D L Amend; J O'Neill; D Norman; W J Jagust; H C Chui; J H Kramer; B R Reed; B L Miller; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

5.  Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's disease.

Authors:  Erika Jonsson Laukka; Sari Jones; Brent J Small; Laura Fratiglioni; Lars Bäckman
Journal:  J Int Neuropsychol Soc       Date:  2004-05       Impact factor: 2.892

6.  Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.

Authors:  Kejal Kantarci; Glenn Reynolds; Ronald C Petersen; Bradley F Boeve; David S Knopman; Steven D Edland; Glenn E Smith; Robert J Ivnik; Eric G Tangalos; Clifford R Jack
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

7.  Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease.

Authors:  Sophie Chantal; Martin Labelle; Rémi W Bouchard; Claude M J Braun; Yvan Boulanger
Journal:  Arch Neurol       Date:  2002-06

8.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease.

Authors:  Sophie Chantal; Claude M J Braun; Rémi W Bouchard; Martin Labelle; Yvan Boulanger
Journal:  Brain Res       Date:  2004-04-02       Impact factor: 3.252

9.  Hippocampus and entorhinal cortex in mild cognitive impairment and early AD.

Authors:  Corina Pennanen; Miia Kivipelto; Susanna Tuomainen; Päivi Hartikainen; Tuomo Hänninen; Mikko P Laakso; Merja Hallikainen; Matti Vanhanen; Aulikki Nissinen; Eeva-Liisa Helkala; Pauli Vainio; Ritva Vanninen; Kaarina Partanen; Hilkka Soininen
Journal:  Neurobiol Aging       Date:  2004-03       Impact factor: 4.673

10.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Authors:  C R Jack; M M Shiung; J L Gunter; P C O'Brien; S D Weigand; D S Knopman; B F Boeve; R J Ivnik; G E Smith; R H Cha; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

View more
  31 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 2.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

Review 3.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

4.  MRI- and MRS-derived hippocampal correlates of quantitative locomotor function in older adults.

Authors:  Molly E Zimmerman; Richard B Lipton; Jullie W Pan; Hoby P Hetherington; Joe Verghese
Journal:  Brain Res       Date:  2009-07-23       Impact factor: 3.252

5.  Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study.

Authors:  Burcu Zeydan; Dinesh K Deelchand; Nirubol Tosakulwong; Timothy G Lesnick; Orhun H Kantarci; Mary M Machulda; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Gülin Öz; Kejal Kantarci
Journal:  J Neuroimaging       Date:  2017-06-29       Impact factor: 2.486

6.  Global N-acetylaspartate in normal subjects, mild cognitive impairment and Alzheimer's disease patients.

Authors:  Lidia Glodzik; Marc Sollberger; Achim Gass; Amit Gokhale; Henry Rusinek; James S Babb; Jochen G Hirsch; Michael Amann; Andreas U Monsch; Oded Gonen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

8.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Authors:  Kejal Kantarci; David S Knopman; Dennis W Dickson; Joseph E Parisi; Jennifer L Whitwell; Stephen D Weigand; Keith A Josephs; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

9.  Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Melissa E Murray; Tanis J Ferman; Nirubol Tosakulwong; Timothy G Lesnick; Mandie Maroney-Smith; Matthew L Senjem; Jeffrey Gunter; Glenn E Smith; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-01-08       Impact factor: 4.673

Review 10.  Proton MRS in mild cognitive impairment.

Authors:  Kejal Kantarci
Journal:  J Magn Reson Imaging       Date:  2013-04       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.